Acadia Pharmaceuticals Inc. Class Action Lawsuit - ACAD

Company
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
Lead Plaintiff Deadline
June 21, 2021 (Expired)
Class Period
June 15, 2020 - April 4, 2021

Expired

Lead Plaintiff Deadline

Jun 21, 2021

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines

WhatsApp

Scan the QR code or click the button to join

Join on WhatsApp

Get Updates by Email

Required Field

Required Field

Required Field

No Spam, opt-out anytime, alert list is free

Allegations

(i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be eligible to join the ACAD class action lawsuit, you must have incurred a loss on shares of Acadia purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Acadia during the relevant time frame or pursuant to the relevant offering(s), you have until June 21, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

TOP